Nicox S.A. (COX.PA)
Nicox S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Valbonne, FR. The stock last traded at $0.58, up 0.00% on the session, giving a market capitalisation of $29.0M. Its beta of 0.97 implies it has historically moved less than the broad market.
Nicox S.A. is an ophthalmology enterprise operating both within France and globally, focused on developing therapies to safeguard vision and enhance overall eye health. Its leading investigational drug, NCX 470, an innovative nitric oxide-donating prostaglandin analog designed to decrease intraocular pressure in individuals with open-angle glaucoma or ocular hypertension, is currently undergoing Phase 3 clinical trials. Furthermore, the company is progressing NCX 4251, a specialized fluticasone formulation, through a Phase 2b clinical trial for the management of acute exacerbations of blepharitis, as well as NCX 1728. Nicox also provides VYZULTA, a latanoprostene bunod ophthalmic solution for treating open-angle glaucoma or ocular hypertension, and ZERVIATE, a cetirizine ophthalmic solution to relieve ocular itching related to allergic conjunctivitis. The company, established in 1996, has its main office situated in Valbonne, France.
Nicox S.A. is most often compared with the following Healthcare names: